Unknown

Dataset Information

0

Local overexpression of interleukin-11 in the central nervous system limits demyelination and enhances remyelination.


ABSTRACT: Demyelination is one of the pathological hallmarks of multiple sclerosis (MS). To date, no therapy is available which directly potentiates endogenous remyelination. Interleukin-11 (IL-11), a member of the gp130 family of cytokines, is upregulated in MS lesions. Systemic IL-11 treatment was shown to ameliorate clinical symptoms in experimental autoimmune encephalomyelitis (EAE), an animal model of MS. IL-11 modulates immune cells and protects oligodendrocytes in vitro. In this study, the cuprizone-induced demyelination mouse model was used to elucidate effects of IL-11 on de- and remyelination, independent of the immune response. Prophylactic-lentiviral- (LV-) mediated overexpression of IL-11 in mouse brain significantly limited acute demyelination, which was accompanied with the preservation of CC1(+) mature oligodendrocytes (OLs) and a decrease in microglial activation (Mac-2(+)). We further demonstrated that IL-11 directly reduces myelin phagocytosis in vitro. When IL-11 expressing LV was therapeutically applied in animals with extensive demyelination, a significant enhancement of remyelination was observed as demonstrated by Luxol Fast Blue staining and electron microscopy imaging. Our results indicate that IL-11 promotes maturation of NG2(+) OPCs into myelinating CC1(+) OLs and may thus explain the enhanced remyelination. Overall, we demonstrate that IL-11 is of therapeutic interest for MS and other demyelinating diseases by limiting demyelination and promoting remyelination.

SUBMITTER: Maheshwari A 

PROVIDER: S-EPMC3683504 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature

altmetric image

Publications

Local overexpression of interleukin-11 in the central nervous system limits demyelination and enhances remyelination.

Maheshwari Anurag A   Janssens Kris K   Bogie Jeroen J   Van Den Haute Chris C   Struys Tom T   Lambrichts Ivo I   Baekelandt Veerle V   Stinissen Piet P   Hendriks Jerome J A JJ   Slaets Helena H   Hellings Niels N  

Mediators of inflammation 20130530


Demyelination is one of the pathological hallmarks of multiple sclerosis (MS). To date, no therapy is available which directly potentiates endogenous remyelination. Interleukin-11 (IL-11), a member of the gp130 family of cytokines, is upregulated in MS lesions. Systemic IL-11 treatment was shown to ameliorate clinical symptoms in experimental autoimmune encephalomyelitis (EAE), an animal model of MS. IL-11 modulates immune cells and protects oligodendrocytes in vitro. In this study, the cuprizon  ...[more]

Similar Datasets

| S-EPMC6660683 | biostudies-literature
| S-EPMC10742427 | biostudies-literature
| S-EPMC8029487 | biostudies-literature
| S-EPMC5438658 | biostudies-literature
| S-EPMC7181452 | biostudies-literature
| S-EPMC10756675 | biostudies-literature
| S-EPMC5669554 | biostudies-literature
| S-EPMC6596867 | biostudies-literature
| S-EPMC6764409 | biostudies-literature
| S-EPMC5563681 | biostudies-other